Notice2026-10813
Government-Owned Inventions; Availability for Licensing
Primary source
Metadata and text below are from the Federal Register, a public-domain U.S. government work. Always verify the official published version before relying on it for any legal matter.
Published
June 1, 2026
Issuing agencies
Health and Human Services DepartmentNational Institutes of Health
Abstract
The National Institute of Allergy and Infectious Diseases (NIAID), an institute of the National Institutes of Health (NIH), Department of Health and Human Services (HHS), is giving notice of the invention listed below, which is owned by an agency of the U.S. Government and is available for licensing to achieve expeditious commercialization of results of federally-funded research and development. Foreign patent applications are filed on selected inventions to extend market coverage for companies and may also be available for licensing.
Full Text
<html>
<head>
<title>Federal Register, Volume 91 Issue 104 (Monday, June 1, 2026)</title>
</head>
<body><pre>
[Federal Register Volume 91, Number 104 (Monday, June 1, 2026)]
[Notices]
[Pages 32405-32406]
From the Federal Register Online via the Government Publishing Office [<a href="http://www.gpo.gov">www.gpo.gov</a>]
[FR Doc No: 2026-10813]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions; Availability for Licensing
AGENCY: National Institutes of Health, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The National Institute of Allergy and Infectious Diseases
(NIAID), an institute of the National Institutes of Health (NIH),
Department of Health and Human Services (HHS), is giving notice of the
invention listed below, which is owned by an agency of the U.S.
Government and is available for licensing to achieve expeditious
commercialization of results of federally-funded research and
development. Foreign patent applications are filed on selected
inventions to extend market coverage for companies and may also be
available for licensing.
FOR FURTHER INFORMATION CONTACT: Inquiries related to this licensing
opportunity should be directed to: Yogikala Prabhu at 202-365-4785, or
<a href="/cdn-cgi/l/email-protection#2851474f414349444906585a494a405d68464140064f475e"><span class="__cf_email__" data-cfemail="6f16000806040e030e411f1d0e0d071a2f01060741080019">[email protected]</span></a>. Licensing information may be obtained by
communicating with the Technology Transfer and Intellectual Property
Office, National Institute of Allergy and Infectious Diseases, 5601
Fishers Lane, Rockville, MD 20852: tel. 301-496-2644. A signed
Confidential Disclosure Agreement will be required to receive copies of
unpublished information related to the invention.
SUPPLEMENTARY INFORMATION: Technology description follows:
Monoclonal Antibody for Specific Detection of the Transcription Factor
Eos (Ikzf4) in Regulatory T Cells
Description of Technology
Regulatory T cells (Tregs) are immune cells that keep the immune
system balanced and prevent autoimmunity. Tregs depend on a protein
called Eos (Ikzf4) that helps turn genes on and off for their
development and function, but until now, antibodies used to detect and
study Eos were unreliable.
Researchers at the National Institute of Allergy and Infectious
Diseases (NIAID) have created monoclonal antibody 18H2 to accurately
detect Eos in mouse and human Treg cells. To make 18H2, they immunized
hamsters with a segment of the Eos protein and used advanced techniques
to select the best antibody-producing cells. The resulting 18H2
antibody specifically detects Eos and does not react with cells lacking
Eos.
The 18H2 antibody stands out by reliably detecting both human and
mouse Eos and performing better in laboratory tests, such as flow
cytometry, used to analyze Treg cells. This technology offers a
powerful new way to study Treg cell development and how Eos helps
protect against autoimmune conditions.
This technology is available for licensing for commercial
development in accordance with 35 U.S.C. 209 and 37 CFR part 404, as
well as for further development and evaluation under a research
collaboration.
Potential Commercial Applications
<bullet> Development of tests that track Treg cell function and Eos
protein levels in patients and monitor Eos levels in autoimmune
diseases, cancer treatments, and organ transplants.
Competitive Advantages
<bullet> Eos-specific detection, confirmed by lack of reactivity in
cells that lack Eos.
<bullet> Detection of both mouse and human Eos, enabling
application to human research.
<bullet> Precise detection and measurement of Treg cells in diverse
sample types.
Development Stage
<bullet> Pre-Clinical
Inventors: Dr. Ethan Shevach, Dr. Angela DeVico, and Ms. Patricia
Korty, all of NIAID.
Publications: Xie X, et al. Eos plays a critical role in Treg
homeostasis and modulates the function of recirculating thymic Tregs in
the control of Treg development. Cell Rep. 2026;45(1):116838.
doi:10.1016/j.celrep.2025.116838.
Intellectual Property: HHS Reference No. E-104-2025-0.
Licensing Contact: To license this technology, please contact
Yogikala Prabhu at 202-365-4785, or <a href="/cdn-cgi/l/email-protection#e49d8b838d8f858885ca949685868c91a48a8d8cca838b92"><span class="__cf_email__" data-cfemail="a6dfc9c1cfcdc7cac788d6d4c7c4ced3e6c8cfce88c1c9d0">[email protected]</span></a>, and
reference E-104-2025-0.
Collaborative Research Opportunity: The National Institute of
Allergy and Infectious Diseases is seeking statements of capability or
interest from parties interested in collaborative research to further
develop, evaluate, or commercialize this technology. Areas of specific
interest include (a) application in pre-clinical models of
autoimmunity, cancer, and transplantation, (b) development of
diagnostic assays for immune monitoring and biomarker discovery, and
(c) inclusion in high-throughput screening platforms for drug discovery
targeting Treg pathways. For
[[Page 32406]]
collaboration opportunities, please contact Yogikala Prabhu at 202-365-
4785, or <a href="/cdn-cgi/l/email-protection#ef96808886848e838ec19f9d8e8d879aaf818687c1888099"><span class="__cf_email__" data-cfemail="21584e46484a404d400f515340434954614f48490f464e57">[email protected]</span></a>.
Dated: May 26, 2026.
Surekha Vathyam,
Director, Technology Transfer and Intellectual Property Office,
National Institute of Allergy and Infectious Diseases.
[FR Doc. 2026-10813 Filed 5-29-26; 8:45 am]
BILLING CODE 4167-05-P
</pre><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script></body>
</html>Indexed from Federal Register on June 1, 2026.
This is legal information, not legal advice. Laws vary by jurisdiction and change frequently. Always verify current law with official sources and consult a licensed attorney in your jurisdiction for advice on your specific situation.